send mail to support@abhimanu.com mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
By Loging in you agree to Terms of Services and Privacy Policy
Claim your free MCQ
Please specify
Sorry for the inconvenience but we’re performing some maintenance at the moment. Website can be slow during this phase..
Please verify your mobile number
Login not allowed, Please logout from existing browser
Please update your name
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Your Free user account at abhipedia has been created.
Remember, success is a journey, not a destination. Stay motivated and keep moving forward!
Refer & Earn
Enquire Now
My Abhipedia Earning
Kindly Login to view your earning
Support
Type your modal answer and submitt for approval
With reference to Umifenovir, consider following statements
Select the correct statement.
1&2 only
2&3 only
1&3 only
All of the above
Recently, CSIR constituent lab CSIR-Central Drug Research Institute(CDRI) Lucknow, has received permission for carrying out Phase III randomised clinical trial of antiviral drug Umifenovir. This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system. Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients. Umifenovir impedes the viral attachment to cells and acts as a viral entry inhibitor and it exhibits modulatory effects on the immune system and induces interferon-production. To evaluate its efficacy in Indian patients, CSIR-CDRI has taken up the clinical trial. Hence all statements are correct.
By: Shubham Tiwari ProfileResourcesReport error
Access to prime resources
New Courses